leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...129130131132133134135136137138139...236237»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. (Pubmed Central) -  Jul 10, 2021   
    CA 19-9 levels after neoadjuvant treatment with FOLFIRINOX predict resectability and survival of PDAC more accurately than dynamic values and should be incorporated into response evaluation and surgical decision-making.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Targeting Pancreatic Ductal Adenocarcinoma (PDAC). (Pubmed Central) -  Jul 10, 2021   
    Treatment with "traditional" anticancer drugs, such as benchmark gemcitabine or the current standard-of-care FOLFIRINOX quaternary combination increase the mean overall survival by only a few months and often leads to chemoresistance...We give an overview of recent developments, touching on the major aspects of PDAC physiology and biochemistry, currently-used and experimental drugs, and targeting technologies under development. A few papers are discussed in some detail to help provide a sense of how the field is moving.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
    Clinical, Retrospective data, Journal:  Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer. (Pubmed Central) -  Jul 9, 2021   
    A few papers are discussed in some detail to help provide a sense of how the field is moving. There were no differences observed in DFS and OS between short-course radiotherapy and long-course chemoradiation, and both can be used as treatment options for patients with locally advanced rectal cancer.
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Jul 9, 2021   
    P1/2,  N=383, Active, not recruiting, 
    There were no differences observed in DFS and OS between short-course radiotherapy and long-course chemoradiation, and both can be used as treatment options for patients with locally advanced rectal cancer. Trial completion date: Apr 2022 --> Oct 2021 | Trial primary completion date: Apr 2022 --> Oct 2021
  • ||||||||||  cisplatin / Generic mfg.
    Review, Journal, IO biomarker:  Systemic therapies for intrahepatic cholangiocarcinoma. (Pubmed Central) -  Jul 9, 2021   
    The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy...Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.
  • ||||||||||  irinotecan / Generic mfg.
    Journal:  Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. (Pubmed Central) -  Jul 9, 2021   
    In vivo, (SN38 + DACHPt)-loaded micelles displayed superior antitumor and antimetastatic activities without impairing safety. Our results suggest that nanomedicine mimicking irinotecan and oxaliplatin as parts of FOLFIRINOX regimen may further improve the feasibility of this multidrug treatment for patients with advanced pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Second-line FOLFOX chemotherapy for advanced biliary tract cancer. (Pubmed Central) -  Jul 9, 2021   
    Our results suggest that nanomedicine mimicking irinotecan and oxaliplatin as parts of FOLFIRINOX regimen may further improve the feasibility of this multidrug treatment for patients with advanced pancreatic cancer. No abstract available
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Successful BRAF/MEK inhibition in a patient with BRAF-mutated extrapancreatic acinar cell carcinoma. (Pubmed Central) -  Jul 8, 2021   
    Therapy was therefore switched to BRAF/MEK inhibition, resulting in almost complete remission and disease control for 12 mo and a remarkable improvement in the patient's general condition. These results indicate that BRAF alterations are a valid therapeutic target in PAC that should be routinely assessed in this patient population.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial initiation date, Metastases:  Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Jul 6, 2021   
    P1,  N=12, Not yet recruiting, 
    The possible drug-drug interaction shown in this study suggests that fluorouracil, rather than capecitabine, could be a more appropriate choice of fluoropyrimidine for patients who are taking PPIs in the treatment of metastatic colorectal cancer. Initiation date: Jun 2021 --> Sep 2021
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Journal, BRCA Biomarker, PARP Biomarker:  Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. (Pubmed Central) -  Jul 4, 2021   
    Olaparib, a PARP inhibitor, has been approved as maintenance for PDAC patients harboring germline BRCA1/2 pathogenic mutations and previously treated with a platinum-based chemotherapy...Failed samples were all from tissue macrosections, which had higher fragmented DNA than standard sections, biopsies and fine-needle aspirations, likely due to fixation procedures. BRCA1/2 testing on pancreatic tumor tissues can also be feasible on small biopsies, but more cases must be analyzed to define its role and value in the PDAC diagnostic algorithm.
  • ||||||||||  Clinical, Review, Journal:  Toxoplasmosis in Pediatric Hematopoietic Stem Cell Transplantation Patients. (Pubmed Central) -  Jul 4, 2021   
    Treatment with oral pyrimethamine, sulfadiazine, and leucovorin for at least 6 weeks is the first-line therapy and should be followed by secondary prophylaxis. In this article, we review the published literature regarding the epidemiology, clinical presentation, treatment, and prevention of toxoplasmosis in HSCT recipients.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Clinical, Journal:  External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. (Pubmed Central) -  Jul 3, 2021   
    Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial...The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%)...We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials.